Webb17 aug. 2024 · Recro Pharma Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, announced its acquisition of IRISYS, a San Diego-based CDMO that possesses capabilities that complement and expand … WebbAsia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market to Touch Valuation of US$ 140.03 Billion by 2031: Astute AnalyticaThe Asia Pacific pharmaceutical CDMO market is poised for significant growth due to factors such as increasing outsourcing of drug development and manufacturing activities by …
Recro Pharma, Exton, Acquires San Diego Competitor in $50 …
Webb13 aug. 2024 · Recro Pharma, a contract development and manufacturing organization (CDMO) specializing in oral solid dose drug products, has acquired fellow CDMO IRISYS. The company was acquired for approximately $50 million in a combination of cash, shares of Recro common stock, and a seller promissory note. WebbRepresented Recro Pharma, Inc. in its acquisition of IRISYS, a San Diego-based CDMO that possesses capabilities that complement and expand those of Recro, for approximately $50m in a combination of cash, shares of Recro common stock and a … our town national endowment for the arts
Asia Pacific Pharmaceutical Contract Development and
Webb16 aug. 2024 · Irisys has about $23 million on hand thanks to its contracted stockpile and “vetted sales pipeline,” Recro stated. With the offer under its belt and $2.1 million in Irisys earnings on the horizon, Recro states it will prepare an upgrade to its monetary assistance in the 3rd quarter. RELATED: News of Note– Recro and Novartis extend pact Webb5 apr. 2024 · Company. Societal CDMO 1 E. Uwchlan Ave Suite 112 Exton, PA 19341 T: 770-531-8365 Webb14 apr. 2024 · Market Scenario. Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market was valued at US$ 60.82 billion in 2024 and is projected to attain a valuation of US$ 140.03 billion by 2031, growing at a CAGR of 9.9% from 2024-2031. The Asia Pacific Pharmaceutical Contract Development and … roguetech battletech mod